Thanks for the link (saw it on SH too).

That's an excellent interview and I would encourage shareholders to have a listen to it if they have a chance. Not really any new info but an update on the continuing initiative to focus on therapeutic applications. It also sounds like they have their work cut out for them and possibly a 5-year window to get the FDA trials done and the co. sold.